[Guidelines for the management of nilotinib ( Tasigna ) -induced side effects in chronic myelogenous leukemia leukemia: recommendations of French Intergroup of CML ( Fi-LMC group ) ] .
Nilotinib ( Tasigna ) is a second-generation BCR-ABL kinase inhibitor , recently introduced and used for the treatment of chronic or accelerated phase CML patients , intolerant or resistant to imatinib .
This treatment represents and important step forward for the disease control of such patients but can lead to side effects , sometimes serious , which can limit its optimal use .
We propose here some guidelines that might be of help in daily practice , in order to manage properly these side effects .
